These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31410730)

  • 1. Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis.
    Wang Y; Zhang Y
    Clin Transl Oncol; 2020 Jun; 22(6):835-843. PubMed ID: 31410730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC).
    Gudbrandsdottir G; Aarstad HH; Bostad L; Hjelle KM; Aarstad HJ; Bruserud Ø; Tvedt THA; Beisland C
    Cancer Immunol Immunother; 2021 Jan; 70(1):19-30. PubMed ID: 32621022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma.
    Dosquet C; Schaetz A; Faucher C; Lepage E; Wautier JL; Richard F; Cabane J
    Eur J Cancer; 1994; 30A(2):162-7. PubMed ID: 8155390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer.
    Kallio J; Hämäläinen M; Luukkaala T; Moilanen E; Tammela TL; Kellokumpu-Lehtinen PL
    Urol Oncol; 2017 Sep; 35(9):544.e25-544.e31. PubMed ID: 28572026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.
    Zhao Z; Liao G; Li Y; Zhou S; Zou H; Fernando S
    PLoS One; 2014; 9(11):e114096. PubMed ID: 25426861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
    Blay JY; Negrier S; Combaret V; Attali S; Goillot E; Merrouche Y; Mercatello A; Ravault A; Tourani JM; Moskovtchenko JF
    Cancer Res; 1992 Jun; 52(12):3317-22. PubMed ID: 1596890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
    Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
    Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
    Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
    Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
    Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
    J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated neutrophil-lymphocyte ratio combined with hyponatremia indicate poor prognosis in renal cell carcinoma.
    Pedersen MM; Donskov F; Pedersen L; Zhang ZF; Nørgaard M
    Acta Oncol; 2020 Jan; 59(1):13-19. PubMed ID: 31448981
    [No Abstract]   [Full Text] [Related]  

  • 11. Preoperative serum total cholesterol is a predictor of prognosis in patients with renal cell carcinoma: a meta- analysis of observational studies.
    Li B; Huang D; Zheng H; Cai Q; Guo Z; Wang S
    Int Braz J Urol; 2020; 46(2):158-168. PubMed ID: 31961621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of hepatic parameters in renal cell carcinoma (RCC) by interleukin-6 (IL-6)?
    Wechsel HW; Feil G; Lahme S; Zumbragel A; Petri E; Bichler KH
    Anticancer Res; 1999; 19(4A):2577-81. PubMed ID: 10470198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics.
    Erdem S; Amasyali AS; Aytac O; Onem K; Issever H; Sanli O
    Urol Oncol; 2014 Oct; 32(7):1031-40. PubMed ID: 25027687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker.
    Väänänen T; Kallio J; Vuolteenaho K; Ojala A; Luukkaala T; Hämäläinen M; Tammela T; Kellokumpu-Lehtinen PL; Moilanen E
    Scand J Urol; 2017 Oct; 51(5):367-372. PubMed ID: 28644702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.
    Cheng B; Yang G; Jiang R; Cheng Y; Yang H; Pei L; Qiu X
    Oncotarget; 2016 Oct; 7(40):65862-65875. PubMed ID: 27588469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis.
    Hu Q; Gou Y; Sun C; Ding W; Xu K; Gu B; Xia G; Ding Q
    Urol Oncol; 2014 Jan; 32(1):50.e1-8. PubMed ID: 24239465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 6 induces cell proliferation of clear cell renal cell carcinoma by suppressing hepaCAM via the STAT3-dependent up-regulation of DNMT1 or DNMT3b.
    Quan Z; He Y; Luo C; Xia Y; Zhao Y; Liu N; Wu X
    Cell Signal; 2017 Apr; 32():48-58. PubMed ID: 28093267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis.
    Shen H; Liu Q; Li M; Yang P
    Clin Invest Med; 2017 Apr; 40(2):E40-E48. PubMed ID: 28447576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretherapeutic Plasma Fibrinogen Level is an Independent Survival Predictor in Renal Cell Carcinoma.
    Sasaki T; Onishi T
    Oncol Res Treat; 2015; 38(7-8):374-8. PubMed ID: 26278582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
    Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
    J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.